ライフサイエンスコーパス: respiratory distress

1 Hoxa5 function causes neonatal death due to respiratory distress.

2 onth to 5 years of age with undifferentiated respiratory distress.

3 ediate delivery group had increased rates of respiratory distress (76 [8%] of 919 vs 47 [5%] of 910,

4 anically activated ion channel Piezo2 causes respiratory distress and death in newborn mice.

5 a first episode of acute bronchiolitis with respiratory distress and no chronic medical condition we

6 nd is a welfare concern, as the incidence of respiratory distress and ocular trauma observed in this

7 leads to motor neuron loss, muscle atrophy, respiratory distress, and death.

8 EGF10 cause early onset myopathy, areflexia, respiratory distress, and dysphagia (EMARDD), a rare con

9 s result in early-onset myopathy, areflexia, respiratory distress, and dysphagia (EMARDD).

10 5 (38.8%) with available data had dyspnea or respiratory distress, and hospitalizations occurred in 1

11 emorrhage, one subarachnoid haemorrhage, one respiratory distress, and one from disease progression t

12 The mean (SD) Respiratory Distress Assessment Instrument score improve

13 respiratory support for preterm infants with respiratory distress has not been proved.

14 y was conducted in 12 patients with moderate respiratory distress (i.e., after partial recovery from

15 mortality in children with undifferentiated respiratory distress in Ghana.

16 al disorder that presents with hypotonia and respiratory distress in neonates.

17 paradigm for developing strategies to treat respiratory distress in SMA.

18 Pediatric acute respiratory distress in tropical settings is very common

19 les collected from 448 pig farms affected by respiratory distress located in the Po Valley.

20 cal disorders (4 patients) and postoperative respiratory distress or failure (4 patients).

21 Shortness of breath, dyspnea, or respiratory distress or failure at hospital admission wa

22 hest indrawing pneumonia and signs of severe respiratory distress, oxygen saturation <93% (when not a

23 Twelve adult patients with respiratory distress symptoms were enrolled in this stud

24 2-year follow-up was in good health with no respiratory distress symptoms.

25 e low tidal volume strategy as per the Acute Respiratory Distress Syndrom Network protocol.

26 rainage (1.7% vs 9.9%, P = 0.006), and acute respiratory distress syndrome (1.7% vs 9.9%, P = 0.006)

27 atients in the placebo group developed acute respiratory distress syndrome (7 vs 0) and required mech

28 a (adjusted HR, 2.10; 95% CI, 1.90-2.33) and respiratory distress syndrome (adjusted HR, 2.43; 2.21-2

29 hock, multiple organ failure including acute respiratory distress syndrome (ARDS) and acute renal fai

30 Sepsis and the acute respiratory distress syndrome (ARDS) are major causes of

31 ed to help drive early pathogenesis in acute respiratory distress syndrome (ARDS) by enhancing neutro

32 3 was also associated with the risk of acute respiratory distress syndrome (ARDS) in an intensive car

33 Acute respiratory distress syndrome (ARDS) is associated with

34 RATIONALE: Acute respiratory distress syndrome (ARDS) is caused by widesp

35 Acute respiratory distress syndrome (ARDS) is characterized by

36 Acute respiratory distress syndrome (ARDS) is undefined in neo

37 lation (MV) remains the cornerstone of acute respiratory distress syndrome (ARDS) management.

38 EP) is unknown in patients with severe acute respiratory distress syndrome (ARDS) on extracorporeal m

39 ent data meta-analysis was to identify acute respiratory distress syndrome (ARDS) patient subgroups w

40 on clinical outcomes in patients with acute respiratory distress syndrome (ARDS) remain uncertain.

41 RATIONALE: Acute respiratory distress syndrome (ARDS) remains a major cau

42 Management of acute respiratory distress syndrome (ARDS) remains largely sup

43 Clinical factors alone poorly explain acute respiratory distress syndrome (ARDS) risk and ARDS outco

44 ATIONALE: We previously identified two acute respiratory distress syndrome (ARDS) subphenotypes in tw

45 Clinicians who treat patients with acute respiratory distress syndrome (ARDS) use information and

46 In the 50 years since acute respiratory distress syndrome (ARDS) was first described

47 RATIONALE: Following acute respiratory distress syndrome (ARDS), joblessness is com

48 el virus that emerged in 2012, causing acute respiratory distress syndrome (ARDS), severe pneumonia-l

49 In clinical trials of therapies for acute respiratory distress syndrome (ARDS), the average treatm

50 anding and management of patients with acute respiratory distress syndrome (ARDS), the morbidity and

51 severe pneumonia is the main cause of acute respiratory distress syndrome (ARDS), we aimed to invest

52 iruses (IAV) can cause lung injury and acute respiratory distress syndrome (ARDS), which is character

53 nniversary of the first description of acute respiratory distress syndrome (ARDS).

54 ilation since the first description of acute respiratory distress syndrome (ARDS).

55 cal ventilation in adult patients with acute respiratory distress syndrome (ARDS).

56 on consensus definition of sepsis and acute respiratory distress syndrome (ARDS).

57 is increasingly used in patients with acute respiratory distress syndrome (ARDS).

58 ffects have never been investigated in acute respiratory distress syndrome (ARDS).

59 th factor (KGF) might be beneficial in acute respiratory distress syndrome (ARDS).

60 n the management of many patients with acute respiratory distress syndrome (ARDS).

61 ome has been as extensively studied as acute respiratory distress syndrome (ARDS).

62 ged as a potential new therapeutic for acute respiratory distress syndrome (ARDS).

63 agement, and outcomes of patients with acute respiratory distress syndrome (ARDS).

64 glycemia (aRR, 1.53; 95% CI, 1.34-1.75), and respiratory distress syndrome (aRR, 1.48; 95% CI, 1.30-1

65 Mechanically ventilated children with acute respiratory distress syndrome (Berlin).

66 vacuolating toxin called community-acquired respiratory distress syndrome (CARDS) toxin is capable o

67 al criteria for sepsis (six trials) or acute respiratory distress syndrome (four trials), use of inva

68 .73; 95% CI, 2.39-5.82; p < 0.001) and acute respiratory distress syndrome (hazard ratio, 2.16; 95% C

69 In a reciprocal multivariate analysis, acute respiratory distress syndrome (n = 299; 36%) demonstrate

70 e associated with a lower incidence of acute respiratory distress syndrome (odds ratio for 30 mg of p

71 icantly associated with development of acute respiratory distress syndrome (odds ratio, 1.31; 95% CI,

72 was associated with the development of acute respiratory distress syndrome (odds ratio, 4.17; 95% CI,

73 .041), the most frequent of which were acute respiratory distress syndrome (one [2%] vs two [4%] pati

74 patients with early moderate to severe acute respiratory distress syndrome (PaO2/FiO2 < 200 and withi

75 PaO2/FIO2 </= 300) and moderate-severe acute respiratory distress syndrome (PaO2/FIO2 </= 150).

76 hods better identified moderate-severe acute respiratory distress syndrome (PaO2/FIO2 </= 150); nonli

77 urve for patients meeting criteria for acute respiratory distress syndrome (PaO2/FIO2 </= 300) and mo

78 However, its role as primary therapy for respiratory distress syndrome (RDS) of prematurity needs

79 for high altitude pulmonary edema (HAPE) and respiratory distress syndrome (RDS) using the software R

80 .5), asphyxia (RR = 8.5, 99% CI: 5.7, 11.3), respiratory distress syndrome (RR = 6.5, 99% CI: 5.9, 7.

81 easured circulating interleukin-17A in acute respiratory distress syndrome 1 and acute respiratory di

82 In acute respiratory distress syndrome 1, we used paired serum an

83 ry distress syndrome onset, whereas in acute respiratory distress syndrome 2, we used plasma obtained

84 te respiratory distress syndrome 1 and acute respiratory distress syndrome 2.

85 Acute respiratory distress syndrome adjudication was performed

86 s ratio, 2.43; 95% CI, 1.68-3.49), and acute respiratory distress syndrome after accounting for the c

87 had a 73% increased risk of developing acute respiratory distress syndrome after controlling for age,

88 births and could be a risk factor to develop respiratory distress syndrome among preterm infants.

89 469 patients (18 tuberculosis-related acute respiratory distress syndrome and 451 acute respiratory

90 re categorized as tuberculosis-related acute respiratory distress syndrome and acute respiratory dist

91 2 alveolar epithelial cells in neonates with respiratory distress syndrome and BPD.

92 venues for therapeutic manipulation in acute respiratory distress syndrome and could have implication

93 hosphoinositide 3-kinase inhibition in acute respiratory distress syndrome and highlight the importan

94 etectable in over 90% of patients with acute respiratory distress syndrome and is associated with deg

95 result in serious outcomes, including acute respiratory distress syndrome and multi-organ failure in

96 veolar lavage fluid from patients with acute respiratory distress syndrome and multiple models of lun

97 ical trials of promising therapies for acute respiratory distress syndrome and reduce the number of l

98 wenty-five patients (19 mild-to-severe acute respiratory distress syndrome and six matched ventilated

99 mized clinical trial of hypothermia in acute respiratory distress syndrome and the feasibility of stu

100 commonly for diagnosis of lung injury (acute respiratory distress syndrome and transfusion-related ac

101 eting lung injury in patients with the acute respiratory distress syndrome are lacking.

102 talized patients at risk of developing acute respiratory distress syndrome at the time of critical ca

103 Patients with acute respiratory distress syndrome at the time of initial con

104 trospective review of 58 patients with acute respiratory distress syndrome based on Berlin criteria a

105 xtracorporeal membrane oxygenation for acute respiratory distress syndrome between 2010 and 2015.

106 Acute respiratory distress syndrome blood and alveolar neutrop

107 ion decreased the inhibitory effect of acute respiratory distress syndrome broncho-alveolar lavage fl

108 lenishment of serum amyloid P-depleted acute respiratory distress syndrome broncho-alveolar lavage fl

109 serve as rescue therapy in refractory acute respiratory distress syndrome but has not been assessed

110 After induction of acute respiratory distress syndrome by hydrochloric acid insti

111 eta agonists may reduce progression to acute respiratory distress syndrome by reducing lung inflammat

112 Only 7 of 133 acute respiratory distress syndrome cases met criteria for eng

113 Acute respiratory distress syndrome continues to represent an

114 Acute respiratory distress syndrome criteria were recorded.

115 bated at the time of meeting all other acute respiratory distress syndrome criteria.

116 nflammatory cytokines were measured on acute respiratory distress syndrome day 1 and correlated with

117 mechanically ventilated patients with acute respiratory distress syndrome demonstrates that implemen

118 Acute respiratory distress syndrome developed in 75 patients (

119 Median time to acute respiratory distress syndrome development was 55.4 days

120 Patients were screened for acute respiratory distress syndrome development within 1 year

121 epsis that correlate with survival and acute respiratory distress syndrome development, thus suggesti

122 linical indices were not predictive of acute respiratory distress syndrome development.

123 and plateau pressure at 24 hours after acute respiratory distress syndrome diagnosis was associated w

124 g pressure evaluated at 24 hours after acute respiratory distress syndrome diagnosis while ventilated

125 drome due to tuberculosis behaves like acute respiratory distress syndrome due to other causes and do

126 Acute respiratory distress syndrome due to tuberculosis behave

127 pared with nonventilated regardless of acute respiratory distress syndrome etiology.

128 Tuberculosis is an uncommon cause of acute respiratory distress syndrome even in high tuberculosis

129 oxygenation therapy in case of severe acute respiratory distress syndrome failing conventional measu

130 Most cases of acute respiratory distress syndrome following hematopoietic st

131 en with indirect lung injury pediatric acute respiratory distress syndrome have a lower risk of morta

132 piratory insufficiency in 141 (11.6%), acute respiratory distress syndrome in 84 (6.9%), pulmonary in

133 Our understanding of the acute respiratory distress syndrome in children is limited, an

134 A significant increase of respiratory distress syndrome in colonized group, even a

135 steroid receipt and the development of acute respiratory distress syndrome in critically ill patients

136 erimental animals and diseases such as acute respiratory distress syndrome in humans.

137 te kidney injury increases the risk of acute respiratory distress syndrome in mechanically ventilated

138 sociated with adverse prognosis in the acute respiratory distress syndrome in small and single-center

139 e associated with a lower incidence of acute respiratory distress syndrome in the 96 hours after ICU

140 xtracorporeal membrane oxygenation for acute respiratory distress syndrome in this group.

141 The incidence and outcomes of acute respiratory distress syndrome in this setting are poorly

142 Forty-two patients with acute respiratory distress syndrome in whom airflow, airway pr

143 Acute respiratory distress syndrome is a frequent complication

144 The acute respiratory distress syndrome is a frequent condition fo

145 Acute respiratory distress syndrome is a multifactorial lung i

146 Whether tuberculosis-related acute respiratory distress syndrome is associated with worse o

147 RATIONALE: Acute respiratory distress syndrome is characterized by alveol

148 ide/formoterol in patients at risk for acute respiratory distress syndrome is feasible and improved o

149 ct of pulmonary arterial compliance in acute respiratory distress syndrome is not established.

150 Acute respiratory distress syndrome led to pulmonary vascular

151 In this experimental model, Acute Respiratory Distress Syndrome Network and open lung appr

152 nary vascular mechanics was similar in Acute Respiratory Distress Syndrome Network and open lung appr

153 Forty-one Acute Respiratory Distress Syndrome Network hospitals across t

154 Forty-two ICUs across 17 Acute Respiratory Distress Syndrome Network hospitals.

155 o 4 hours ventilation according to the Acute Respiratory Distress Syndrome Network protocol or to an

156 Open lung approach as compared to Acute Respiratory Distress Syndrome Network was associated wit

157 r levels in 194 patients, including 38 acute respiratory distress syndrome nonsurvivors.

158 Cdyn, and PaO2/FIO2 were collected at acute respiratory distress syndrome onset and at 24 hours in 3

159 dal volume ventilation within 1 day of acute respiratory distress syndrome onset for greater than or

160 volume during the first 72 hours after acute respiratory distress syndrome onset was never less than

161 At acute respiratory distress syndrome onset, neither mechanical

162 id samples obtained within 48 hours of acute respiratory distress syndrome onset, whereas in acute re

163 zed ventilator settings 24 hours after acute respiratory distress syndrome onset.

164 dal volume ventilation within 1 day of acute respiratory distress syndrome onset.

165 f tumorigenicity-2) within 24 hours of acute respiratory distress syndrome onset.

166 reated with high-flow nasal cannula at acute respiratory distress syndrome onset.

167 annula and those who were intubated at acute respiratory distress syndrome onset.

168 .21-1.42) and the composite outcome of acute respiratory distress syndrome or death (odds ratio, 1.26

169 % CI, 2.26-7.72), composite outcome of acute respiratory distress syndrome or death (odds ratio, 2.43

170 ty troponin I (Abbott ARCHITECT), with acute respiratory distress syndrome outcomes, we measured high

171 analysis of all subjects admitted with acute respiratory distress syndrome over the last 16 years.

172 edside to predict the risk of death of acute respiratory distress syndrome patients 24 hours after di

173 r model using individual data from 478 acute respiratory distress syndrome patients and assessed its

174 hdrawal than moderate/severe pediatric acute respiratory distress syndrome patients managed without e

175 ndrome and the feasibility of studying acute respiratory distress syndrome patients receiving neuromu

176 were higher in both groups of matched acute respiratory distress syndrome patients than in both cont

177 does not cause hypothermia but allowed acute respiratory distress syndrome patients to be effectively

178 omarkers of inflammation and injury to acute respiratory distress syndrome patients undergoing direct

179 One thousand fifty-seven acute respiratory distress syndrome patients were included.

180 eated with high-flow nasal cannula and acute respiratory distress syndrome patients who were directly

181 Nine hundred thirty-four ventilated acute respiratory distress syndrome patients with a central ve

182 uid management decreases mortality for acute respiratory distress syndrome patients with a low initia

183 pective hypothermia treatment in eight acute respiratory distress syndrome patients with PaO2/FIO2 le

184 Obesity has a complex impact on acute respiratory distress syndrome patients, being associated

185 licability in a separate cohort of 300 acute respiratory distress syndrome patients.

186 nnula patients should be considered as acute respiratory distress syndrome patients.

187 trial of hypothermia in patients with acute respiratory distress syndrome receiving treatment with n

188 ssessed the incidence and mortality of acute respiratory distress syndrome reported in children in st

189 with worse outcomes when compared with acute respiratory distress syndrome secondary to other causes

190 ally ventilated burn patients, whereas acute respiratory distress syndrome similarly demonstrates a s

191 A derivation cohort from three acute respiratory distress syndrome studies was used to estima

192 onary arterial compliance increased in acute respiratory distress syndrome survivors and remained unc

193 l discharge, greater than one third of acute respiratory distress syndrome survivors had muscle weakn

194 Given high co-occurrence, acute respiratory distress syndrome survivors should be simult

195 ric symptoms occurred in two thirds of acute respiratory distress syndrome survivors with frequent co

196 In a multisite cohort of long-term acute respiratory distress syndrome survivors, better annual p

197 ventricular load improve over time in acute respiratory distress syndrome survivors.

198 evaluating the 4-m gait speed test in acute respiratory distress syndrome survivors.

199 One hundred fifty-six acute respiratory distress syndrome survivors.

200 ntilation, the mean (SD) percentage of acute respiratory distress syndrome time it was used was 59.1%

201 impact of right ventricular protective acute respiratory distress syndrome treatment on right ventric

202 Acute respiratory distress syndrome trials powered for mortali

203 ensive studies of myocardial injury in acute respiratory distress syndrome using modern high-sensitiv

204 n the two groups (tuberculosis-related acute respiratory distress syndrome vs acute respiratory distr

205 and PICU-based incidence of pediatric acute respiratory distress syndrome was 3.5 (95% CI, 2.2-5.7)

206 Acute respiratory distress syndrome was induced by Escherichia

207 Acute respiratory distress syndrome was induced by repeated lu

208 Acute respiratory distress syndrome was induced combining sali

209 Mild acute respiratory distress syndrome was induced in 10 anesthet

210 Acute respiratory distress syndrome was induced in rats by int

211 The main reason for acute respiratory distress syndrome was pneumonia in 81% of pa

212 iratory distress syndrome-others) with acute respiratory distress syndrome were admitted.

213 ts (5%) with moderate/severe pediatric acute respiratory distress syndrome were supported on extracor

214 gency department patients experiencing acute respiratory distress syndrome while in the emergency dep

215 spective analysis of 363 subjects with acute respiratory distress syndrome who had complete baseline

216 t pneumonia that rapidly progresses to acute respiratory distress syndrome with a fatal outcome remin

217 The unadjusted occurrence rate of acute respiratory distress syndrome within 96 hours of ICU adm

218 auma, infection, sepsis, endotoxin and acute respiratory distress syndrome) and matched mouse models,

219 ix matched ventilated controls without acute respiratory distress syndrome) were enrolled.

220 o-venous) for medical indications (78% acute respiratory distress syndrome).

221 Of 457 patients with acute respiratory distress syndrome, 106 (23%) were not intuba

222 In preterm lambs with severe respiratory distress syndrome, aerosol surfactant admini

223 led, including 47 meeting criteria for acute respiratory distress syndrome, and 32 failed noninvasive

224 patients with sepsis and septic shock, acute respiratory distress syndrome, and major trauma have bee

225 ower incidence of acute kidney injury, acute respiratory distress syndrome, and need for vasopressors

226 scular resistance predict mortality in acute respiratory distress syndrome, and pulmonary arterial co

227 ggest hypothermia may be beneficial in acute respiratory distress syndrome, but cooling causes shiver

228 In pulmonary acute respiratory distress syndrome, but not in extrapulmonary

229 a major cause of acute lung injury and acute respiratory distress syndrome, characterized by alveolar

230 The diseases reviewed include acute respiratory distress syndrome, chronic obstructive pulmo

231 t a promising therapeutic strategy for acute respiratory distress syndrome, clinical translation face

232 In acute respiratory distress syndrome, conservative fluid manage

233 During the acute respiratory distress syndrome, epithelial cells, primari

234 , reason for connection different from acute respiratory distress syndrome, higher simplified acute p

235 gnificant gaps in our understanding of acute respiratory distress syndrome, in part due to the lack o

236 r of significant human pathologies including respiratory distress syndrome, lung adenocarcinoma, and

237 In pediatric acute respiratory distress syndrome, lung injury is mediated b

238 dministered intratracheally (pulmonary acute respiratory distress syndrome, n = 12) or intraperitonea

239 ) or intraperitoneally (extrapulmonary acute respiratory distress syndrome, n = 12).

240 for various pulmonary diseases such as acute respiratory distress syndrome, pneumonia, cystic fibrosi

241 monary embolism, deep vein thrombosis, acute respiratory distress syndrome, pneumonia, decubitus ulce

242 In pediatric acute respiratory distress syndrome, pro- and anti-inflammator

243 ilure Assessment, PaO2/FIO2, origin of acute respiratory distress syndrome, steroids, renal failure a

244 ultivariable adjustment, age, cause of acute respiratory distress syndrome, temperature, heart rate,

245 ss syndrome, but not in extrapulmonary acute respiratory distress syndrome, variable ventilation 1) d

246 In lung tissue from patients with acute respiratory distress syndrome, we identified increased e

247 ere associated with the development of acute respiratory distress syndrome, whereas other traditional

248 After inducing acute respiratory distress syndrome, Z0 and effective arterial

249 cute respiratory distress syndrome and acute respiratory distress syndrome-others and were managed wi

250 respiratory distress syndrome and 451 acute respiratory distress syndrome-others) with acute respira

251 acute respiratory distress syndrome vs acute respiratory distress syndrome-others; 27.7% vs 28.2%; p

252 Consecutive subjects with acute respiratory distress syndrome.

253 associated with mortality in pediatric acute respiratory distress syndrome.

254 d 778 patients with moderate to severe acute respiratory distress syndrome.

255 IO2 ratio, gender, and the etiology of acute respiratory distress syndrome.

256 by increasing their susceptibility to acute respiratory distress syndrome.

257 ciated with a lower incidence of early acute respiratory distress syndrome.

258 e option for future clinical trials in acute respiratory distress syndrome.

259 for treatment of pathological states such as respiratory distress syndrome.

260 pulmonary vascular mechanics in early acute respiratory distress syndrome.

261 3, 6, 12, 24, 36, and 48 months after acute respiratory distress syndrome.

262 4 months thereafter, until 5 years postacute respiratory distress syndrome.

263 rotective ventilation in patients with acute respiratory distress syndrome.

264 ated with lower mortality in pediatric acute respiratory distress syndrome.

265 in predicting outcome in patients with acute respiratory distress syndrome.

266 the severity of rodent E. coli-induced acute respiratory distress syndrome.

267 d-expiratory pressures in experimental acute respiratory distress syndrome.

268 delivery of exogenous surfactant in neonatal respiratory distress syndrome.

269 ean Consensus Conference definition of acute respiratory distress syndrome.

270 ilation 11.4% of the time patients had acute respiratory distress syndrome.

271 me ventilation lowers mortality in the acute respiratory distress syndrome.

272 rotective ventilation in patients with acute respiratory distress syndrome.

273 tilation may depend on the etiology of acute respiratory distress syndrome.

274 ated with lung stress and mortality in acute respiratory distress syndrome.

275 irect lung injury leading to pediatric acute respiratory distress syndrome.

276 greater than or equal to 2 years after acute respiratory distress syndrome.

277 ain pathophysiologic mechanisms of the acute respiratory distress syndrome.

278 with low tidal volume ventilation for acute respiratory distress syndrome.

279 ted with lung connective tissue during acute respiratory distress syndrome.

280 bo for patients with sepsis-associated acute respiratory distress syndrome.

281 permeability, and organ dysfunction in acute respiratory distress syndrome.

282 h the emergency department at risk for acute respiratory distress syndrome.

283 tem-modulating agents for treatment of acute respiratory distress syndrome.

284 jor risk factor for the development of acute respiratory distress syndrome.

285 developing age-tailored therapies for acute respiratory distress syndrome.

286 n broncho-alveolar lavage fluid during acute respiratory distress syndrome.

287 al of conservative fluid management in acute respiratory distress syndrome.

288 AERD), inflammatory bowel disease, and acute respiratory distress syndrome.

289 hanical ventilation and development of acute respiratory distress syndrome.

290 ds and beta agonists for prevention of acute respiratory distress syndrome.

291 d during mechanical ventilation in the acute respiratory distress syndrome.

292 T cell therapy; five met criteria for acute respiratory distress syndrome.

293 rs old, with moderate/severe pediatric acute respiratory distress syndrome.

294 lled in previously completed trials of acute respiratory distress syndrome.

295 ion >/=24 h, stillbirth, or neonatal death); respiratory distress syndrome; any mechanical ventilatio

296 adverse prognosis in patients with the acute respiratory distress syndrome; however, the prognostic i

297 vely, none of SEAP group showed any signs of respiratory distress; the inner surface of the implant e

298 antile haemangioma (causing heart failure or respiratory distress), tumours posing functional risks (

299 Low birthweight and/or respiratory distress were reported in 11 (29%) infected

300 tational age, >/=28 weeks 0 days) with early respiratory distress who had not received surfactant rep